TherOx gets FDA panel date
This article was originally published in The Gray Sheet
FDA's Circulatory System Devices Panel will meet March 18 in Gaithersburg, Md., to vote on a pre-market approval application for the firm's Aqueous Oxygen System for acute myocardial infarction patients who have undergone successful revascularization up to six hours after symptom onset. The system is used to hyperoxygenate and reinfuse a patient's blood at the infarction site
You may also be interested in...
To be more transparent and allow more public discourse, the HHS now requires all its agencies to publish documents it uses to rationalize proposed rules and demonstration projects.
Dr Reddy's is poised to expand its OTC offering in Russia and certain CIS countries by snapping up a basket of allergy brands from India's Glenmark.
Second read-out maintains 94% level of efficacy, with a very early signal that it could outperform Pfizer’s rival mRNA candidate in preventing severe cases.